LL-37, human 是一種由37 個氨基酸殘基組成的兩親性組織蛋白酶衍生的抗菌肽，具有廣泛的抗菌活性。它有助于保護角膜免受感染，對于傷口愈合有著良好的促進作用，同時對多種革蘭氏陽性和革蘭氏陰性病原體具有抗菌和抗生物膜活性。

LL-37, human is a 37-residue, amphipathic, cathelicidin-derived antimicrobial peptide, which exhibits a broad spectrum of antimicrobial activity. LL-37, human could help protect the cornea from infection and modulates wound healing.

LL-37是一種具有血管生成活性的抗菌肽。它對應于人組織蛋白酶抗菌蛋白hCAP18/LL-37的C末端序列（134-170），并通過蛋白水解過程從hCAP18/LL-37細胞外釋放。hCAP18/LL-37是先天免疫系統(tǒng)的效應器，在白細胞和上皮細胞中表達，與炎癥和損傷相關上調?？梢宰C明hCAP18/LL-37在一系列乳腺癌中的過表達。LL-37被認為部分通過甲酰肽受體樣1（FPRL1）刺激上皮細胞增殖，因為用百日咳毒素阻斷受體會使LL-37的增殖作用降低約50%。

LL-37 is an antimicrobial peptide with angiogenic activity. It corresponds to the C-terminal sequence (134-170) of the human cathelicidin antimicrobial protein hCAP18/LL-37 and is extracellularly released from hCAP18/LL-37 by proteolytic processing. hCAP18/LL-37 is an effector of the innate immune system and is expressed in leukocytes and epithelial cells where it is upregulated in association with inflammation and injury. An overexpression of hCAP18/LL-37 in a series of breast carcinomas could be demonstrated. LL-37 has been suggested to stimulate epithelial cell proliferation partially through formyl peptide receptor-like 1 (FPRL1) since blocking the receptor with pertussis toxin decreased the proliferative effect of LL-37 by approximately 50 %.